Live
- Meta Unveils Ray-Ban Smart Glasses Update for WhatsApp Video Calls
- Barrelakka files nomination as Nagarkurnool candidate
- BRS chief KCR to Embark on Bus Yatra Ahead of Parliamentary Elections from today
- Congress still undecided
- All-time highest score by Narayana student in AP SSC results
- TS Inter results announced, here is the direct link
- KTR rallies support for Praveen Kumar
- Deadline for submission of nominations for fourth phase elections to end tomorrow
- WhatsApp Update: WhatsApp to Bring In-App Dialer Feature for Calling Unsaved Contacts
- Kanna Lakshminarayana Leads Election Campaign in Amaravati Supporting Alliance Candidate
Aragen collaborates with NeoVac
Aragen Life Sciences Pvt Ltd, a Hyderabad-based research and development service provider, announced that it has entered into an agreement with UK-based company NeoVac for manufacturing a lipid product that will support the development of lipid nanoparticles (LNP) for use in developing RNA vaccines, for various diseases.
Hyderabad: Aragen Life Sciences Pvt Ltd, a Hyderabad-based research and development service provider, announced that it has entered into an agreement with UK-based company NeoVac for manufacturing a lipid product that will support the development of lipid nanoparticles (LNP) for use in developing RNA vaccines, for various diseases.
Aragen has been working with NeoVac since early December 2021 on process research development (PRD) for the lipid product.
Dr Ramesh Subramanian, Chief Commercial Officer, Aragen said, "Having been associated with the project at the development phase will enable a seamless transition to the manufacturing phase. This collaboration validates Aragen's capabilities across discovery, development and manufacturing to support our customers develop products for the betterment of people across the globe."
NeoVac creates proprietary next generation LNP to enable better RNA vaccines for various diseases. The LNPs are being developed using cutting-edge technology that makes RNA vaccines more thermostable and accessible with broader capabilities and fewer side effects.
NeoVac CEO, Eran Eilat added, "Our partnership with Aragen during the development phase has been fruitful and we are happy to extend the collaboration into the manufacturing phase."
